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Abstract
Omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation may be
beneficial in the treatment of several psychiatric disorders, including
depression. A small number of studies have suggested that there may also
be cognitive and mood effects in healthy samples. The purpose of the
present study was to investigate the effects of n-3 PUFA on depression-
relevant cognitive functioning in healthy individuals. Fifty-four healthy
university students were randomized to receive either n-3 PUFA
supplements or placebo for 4 weeks in a double-blind design. The test
battery included measures of cognitive reactivity, attention, response
inhibition, facial emotion recognition, memory and risky decision-making.
Results showed few effects of n-3 PUFAs on cognition and mood states.
The n-3 PUFA group made fewer risk-averse decisions than the placebo
group. This difference appeared only in non-normative trials of the
decision-making test, and was not accompanied by increased
impulsiveness. N-3 PUFAs improved scores on the control/perfectionism
scale of the cognitive reactivity measure. No effects were found on the
other cognitive tasks and no consistent effects on mood were observed.
The present findings indicate that n-3 PUFA supplementation may have a
selective effect on risky decision making in healthy volunteers, which is
unrelated to impulsiveness.
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Introduction
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are long-
chain polyunsaturated fatty acids found mainly in fish oil and
include eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA). Beneficial effects of n-3 FAs have been reported for a
range of psychiatric disorders, including mood disorders,
schizophrenia and dementia (Freeman, 2000; Young and Con-
quer, 2005). N-3 PUFAs may affect neuronal functioning
through several mechanisms (see Parker, et al., 2006), including
decrease of the production of inflammatory eicosanoids from
arachidonic acid; inhibition of the release of proinflammatory
cytokines and increase of brain-derived neurotrophic factor.
Furthermore, DHA has a role in membrane integrity and flu-
idity, affecting neurotransmission (Yehuda, et al., 1999). Ani-
mal studies have shown that n-3 PUFAs deficiencies may affect
dopaminergic and serotonergic neurotransmission (De la Presa
and Innis, 1999; Chalon, 2006). A reduction of serotonin
release was found in the hippocampus of rats chronically defi-
cient in n-3 PUFAs (Kodas, et al., 2004). In humans, DHA
correlated with the concentration of serotonin metabolites in
cerebrospinal fluid (Hibbeln, et al., 1998).
Supporting evidence for the effects of n-3 PUFAs has been
reported for conditions characterized by impulsivity (reviewed
by Hallahan and Garland, 2004). Two recent meta-analyses
have evaluated the effects of n-3 PUFAs on depressed mood.
Lin and Su (2007) concluded that there is a moderate effect of
n-3 PUFA supplementation on depressed mood in patients
with mood disorders. There was some evidence for a dose–
response relationship, but publication bias was also considered
likely. Appleton, et al. (2007) evaluated randomized controlled
trials in various populations, including not only psychiatric
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populations but also patients with angina and healthy samples.
They concluded that there is little evidence that n-3 PUFAs
improve mood. Although these authors also found a medium
effect size in trials involving patients with mood disorders, they
argue that results are hard to interpret because of the heteroge-
neity of interventions, measures and populations, and because
of probable publication bias. In almost all trials, patients
received n-3 PUFAs in addition to antidepressant medication.
Investigation of healthy samples avoids possible confoun-
ders such as varying remission status and adjunctive treatment.
Although subjective improvement of mood is not to be
expected from short-term treatment with n-3 PUFAs in healthy
individuals, cognitive functions may be affected. Research on
the effects of anti-depressants has shown that cognitive effects
may occur independently from symptom changes and that
these effects may appear in healthy individuals even after one
dosage. For instance, a single dose of citalopram improved
accuracy and speed of recognition of facial expressions of fear
without affecting mood (Harmer, et al., 2003; Browning, et al.,
2007). These findings suggest that cognitive tests may be more
sensitive to the early effects of antidepressants than subjective
mood states. The effects were also selective as they were only
evident in tasks involving emotional information processing
(review in Merens, et al., 2007).
Research on the effects of n-3 PUFAs supplements in
healthy subjects has been quite limited. Hamazaki, et al.
(1996) found that 1.5–1.8 g DHA/day for 3 months prevented
a rise of aggression during mental stress periods in healthy stu-
dents. Fontani, et al. (2005) investigated the effects of 5-week
supplementation of n-3 PUFAs (1.6 g EPA, 0.8 g DHA) versus
placebo. The n-3 PUFA group had improved self-reported
anger, anxiety, fatigue, depression, confusion and vigour scores
and faster reaction times on a go/no-go task and a sustained-
attention task. EEG recordings showed greater amplitudes of
the negative wave preceding and of the positive peak following
the stimuli (CNV and P3) during the go/no-go task. All parti-
cipants in this trial were regular exercisers (>4 h/week), which
reduces generalization. More importantly, the reported effects
appear rather small and inadequately analysed. Paired t-tests
showed significant changes in the n-3 PUFA group and not
in the placebo group; however, analysis of variance tests were
not conducted and the data for the placebo group were not
reported. Hence, we cannot be sure that the improvements in
the n-3 PUFA group were significantly larger than changes in
the placebo group.
The purpose of the present study was to examine the effects
of n-3 PUFAs on depression-related cognition in healthy
volunteers. On the contrary, with Fontani, et al. (2005), parti-
cipants were not selected on the basis of physical fitness and
tests were chosen that are relevant to depression. The test bat-
tery measured attention to emotional stimuli, response inhibi-
tion, facial expression recognition and risky decision-making.
The effects on mood and neutral information processing were
also examined, allowing us to compare our findings with Fon-
tani, et al. (2005); however, the primary outcome measure was
emotional information processing. We selected a number of
cognitive tests, which in previous studies have been shown sen-
sitive to neurotransmitter manipulations in healthy samples
(Merens, et al., 2007) or to depression vulnerability (Austin,
et al., 2001). For example, subjects’ processing of reward and
punishment cues when making risky choices are partly disso-
ciable following manipulations of serotonin (Rogers, et al.,
2003), noradrenaline (Rogers, et al., 2004), dopamine (Scarna,
et al., 2005) and cannabinoid systems (Rogers, et al., 2007).
Materials and methods
Participants
Eligible participants were healthy individuals with a body mass
index (BMI) between 18 and 27, who maintained a regular diet
containing fish not more than once a week. Exclusion criteria
were a current episode of major depression (current = month
before the study), current or previous psychosis, current substance
abuse or previous substance dependence, any illness requiring
medication, smoking or current use of soft drugs, hard drug use
(lifetime) and more than three alcoholic consumptions/day.
Dietary supplements, design
A double-blind randomized controlled trial was carried out.
Participants took 3 g fish oil or olive oil (placebo) per day, pro-
vided in three soft-gel capsules, for 4 weeks. The fish oil con-
tained 2.3 g of n-3 PUFA (1.74 g EPA, 0.25 g DHA). The dose
and duration were chosen on the basis of a consensus paper
(Freeman, et al., 2006), and was comparable with Fontani,
et al. (2005). Both the fish-oil and placebo capsules were
lemon-flavoured to maintain the blind. Randomization was
carried out in blocks of six. The study was approved by the
Medical Ethics Committee of Leiden University Medical
Center.
Measures
Interview and self-report measures The expanded version of
the Mini International Neuropsychiatric Interview (M.I.N.I.
PLUS; Sheehan and Lecrubier, 2006) was used to assess curren-
t and lifetime DSM-IV diagnoses. The Beck Depression Inven-
tory – II (BDI – II; Beck, et al., 1988; Van der Does, 2002b) was
used to measure symptoms of depression during the past
2 weeks. Mood states during the past week were measured
with the shortened Profile of Mood States (POMS) (McNair,
et al., 1971; Wald and Mellenbergh, 1990). The subscales are
sadness, anger, fatigue, tension and vigour. Personality traits
were assessed with the Behavioral Inhibition/Behavioral Activa-
tion Scales (BIS/BAS) scales (Carver and White, 1994). The BIS
is sensitive to signals of punishment, non-reward and novelty
and the BAS has three subscales: Drive, Fun Seeking and
Reward Responsiveness. Finally, cognitive reactivity was mea-
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sured with the Leiden Index of Depression Sensitivity – Revised
(LEIDS-R; Van der Does, 2002a; Van der Does and Williams,
2003). The subscales are Hopelessness/Suicidality (HOP); Accep-
tance/Coping (ACC); Aggression (AGG); Control/Perfectionism
(CTR); Risk Aversion (RAV) and Rumination (RUM). The
scale has been found to discriminate between never-depressed and
recovered-depressed individuals (Van der Does, 2002a; Merens,
et al., 2005) and predicts response to serotonin challenge (Booij
and Van der Does, 2007).
Neutral and emotional information processing tests An
Affective Go/No-Go task was used, consisting of eight blocks
of 16 stimuli. In each block, single words were presented with
a stimulus interval of 1200 ms. Half of the stimuli were positive
words (e.g., happy, clean) and half were negative (e.g., sad,
guilt). In each block, either the positive (P) or negative (N)
words were designated ‘targets’. The blocks were presented in
a NNPPNNPP or PPNNPPNN order. Because of this arrange-
ment, three blocks were ‘shift’ blocks, where participants had
to withhold responding to stimuli that were targets in the pre-
vious block, and four blocks were ‘non-shift’ blocks.
An Attentional Go/No-Go task was also used, with para-
meters identical to the Affective Go/No-Go task, except that
letters and digits were used as targets.
The Facial Expression Recognition Task features five basic
emotions (happiness, sadness, fear, anger and disgust) taken
from the Pictures of Facial Affect Series (Ekman and Friesen,
1976). A male and female examples of these pictures were
morphed between each prototype and neutral in 10% steps.
Four trials of each emotion were presented at each intensity
level. These stimuli were presented in randomized order for
500 ms and replaced by a blank screen. Participants were
asked to respond as quickly and accurately as possible.
The 15 words test was used to assess memory performance
(Saan and Deelman, 1986). A list of 15 unrelated, neutral words
was presented from tape. Immediate recall was tested after each
of the two consecutive presentations. Participants continued
with non-verbal tasks and after 20 min delayed recall was
tested. Parallel versions were used at each session in a random-
ized sequence. Immediate recall was defined as the total of cor-
rect words at the second trial; consolidation as the number of
correct words at delayed recall compared with the second trial.
The Decision-making (gambling) task measures decision-
making behaviour over a variety of differentially weighted con-
tingencies and also distinguishes risk-seeking from risk-aversive
behaviour. It has been previously described in detail by Rogers,
et al. (2003). On each trial, participants were asked to choose
between two simultaneously presented gambles. Each gamble
was visually represented by a histogram, the height of which
indicated the probability of gaining a given number of points
(see Figure 1A). The possible gains were indicated in green ink
above the histogram and the potential losses were indicated in
red ink below the histogram. One gamble (coloured yellow)
was always the control gamble, which had a 0.50 probability
of winning 10 points and a 0.50 chance of losing 10 points
(with an expected value of 0). The alternative ‘experimental’
gamble (coloured blue) varied in the probability of winning,
which was either high or low (0.60 vs 0.40), possible gains,
which were either large or small (70 vs 30 points) and possible
losses, which were either large or small (70 vs 30 points). These
variables were crossed to produce eight trial types in which the
expected value of the ‘experimental’ gamble varied between
−20 and +20. The control and the ‘experimental’ gamble
appeared randomly on the left or right. The participants indi-
cated their choice by a key press. Dependent measures were the
proportion of choices of the ‘experimental’ over the control
gamble as a function of its probability of winning, size of pos-
sible gains and the size of possible losses and the mean deliber-
ation time (ms) for these choices.
Two extra trial types were also included that represented
choices between gambles known to be subject to the non-
normative biases of risk-aversion and risk-seeking choices and
that cannot be explained by decision-makers choosing actions
that maximize expected value (the ‘reflection effect’; see Kah-
neman and Tversky, 1979). The first such trial type was a
‘gains-only’ trial in which the participants were presented with
a choice between a guaranteed win of 30 points versus a 0.5
chance of winning 60 points and a 0.5 chance of losing 0 points
(see Figure 1B). Neither option had any associated losses. On
the contrary, the second trial type was a ‘losses-only’ trial in
which the participants were presented with a choice between a
guaranteed loss of 30 points versus a 0.5 chance of losing
60 points and a 0.5 chance of losing 0 points. Neither option
had any potential gains. Within both the ‘gains-only’ and
‘losses-only’ trial types, the expected value of each gamble
was equal; however, decision-makers usually exhibit risk-
aversion in the former case but risk-seeking behaviour in the
latter case (Schneider and Lopes, 1986).
The 10 trial types were presented pseudorandomly within
four blocks of 20 trials. Across the four blocks, there were
eight repetitions of each ‘experimental’ gamble and eight repe-
titions of each of the ‘gains-only’ and the ‘losses-only’ trial
types. To maintain participants’ interest in the test, a monetary
reward of 1 eurocent was placed on each point. Participants
started off each block of trials with 100 cents and could keep
the average gain of all the blocks (total gains were typically
around 3 euros). Visual feedback was given after each choice
and the revised points total was presented for 2 s before the
next trial. At the end of each block, the participants were
given a final score for that block. This task was administered
only at post-treatment, as previous pharmacological studies of
decision-making involving within-subject designs have found
significant order effects (Wood, et al., 2006).
Manipulation check
Immediately before and after treatment, fatty acid composition
was determined in plasma to measure compliance and to detect
possible increased fish or fish oil consumption in the placebo
group. Venous blood was obtained (10 mL) in sodium heparin
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tubes. After sampling, it was immediately placed on ice and
centrifuged for 20 min at 2650 × gmax. The samples were stored
at −80 °C until analysis by gas chromatography. Self-reported
compliance and the success of blinding were checked by a ques-
tionnaire after completion of the study.
Procedure
Participants were recruited through advertisements. The
screening session started with the informed consent procedure,
followed by the M.I.N.I.-PLUS and a check of the other in-
and exclusion criteria. In a subsequent session a few days
later, blood sample was taken, and the questionnaires and
tests were administered (t0). The intake of supplements started
the same day. The cognitive tests and the POMS were re-
administered 1 week later (t1), and 4 weeks later the same pro-
cedure was repeated as at pre-treatment with the addition of
the decision-making task (t4). All measurements were taken at
the same time of the day for each participant. Participants
received 45 euros.
Statistical analysis
The questionnaires and the cognitive tasks were analysed using
repeated measures analysis of variance (rmANOVA), with
treatment group (n-3 PUFAs versus placebo) as between-
subjects factor and time (t0, t1, t4) as within-subjects factor.
Data of the Affective Go/No-Go task were analysed with addi-
tional within-subject factors target valence and shift condition.
Dependent measures for the Go/No-Go tasks were omissions
(failures to respond to targets), false alarms and reaction
times for hits. For the emotion recognition task, accuracy
data were analysed with rmANOVA for each emotion sepa-
rately (with time and intensity as within-subject factors). Reac-
tion times were examined with emotion and time as within-
subject factors. The 15-words list task had recall condition
(immediate versus delayed) as additional within-subject factor.
For the decision-making task, the proportionate choice data
and mean deliberation times were analysed with rmANOVAs
with between-subject factor of treatment, and within-subject
factors of probability of winning, size of possible gains and
size of possible losses. The ‘gains-only’ and ‘losses-only’ trials
were analysed with rmANOVA with between-subject factor of
treatment and within-subject factor of trial type.
Results
Data screening
Before analysis, all data were examined for accuracy of data-
entry, missing values and normal distribution assumptions.
Scores were normally distributed after square root transforma-
tions were performed on the POMS subscales, on the HOP
Figure 1 An example visual display from the decision-making task,
consisting of an ‘experimental’ gamble with a 0.40 chance of winning 70
points and a 0.60 probability of losing 30 points versus the control gamble
with a 0.50 chance of winning 10 points and a 0.50 of losing 10 points
(Panel A). A ‘Gains only’ trial consisting of a certain win of 30 points and a
gamble with a 0.50 probability of winning 60 points or 0 points (Panel B).
A ‘Losses only’ trial consisting of a certain loss of 30 points and a gamble
with a 0.50 probability of losing of 60 points or 0 points (Panel C).
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subscale of the LEIDS-R and on the misses and false alarms of
the attentional and affective go/no-go tasks (tables show
untransformed values). Extreme outlying data (z > |3|) were
removed from the analysis if not corrected by transformations.
For the decision-making task, proportionate choice data were
arcsine-transformed.
Participant characteristics
Fifty-four of the 56 participants completed the study. The two
dropouts stopped soon after the first measurement: one because
of having difficulty swallowing the capsules and the second one
because of personal problems unrelated to the experiment.
These participants were not included in the analyses. The
demographic characteristics of the participants are shown in
Table 1. No group differences were found with respect to age,
gender (χ2(1) = 0.9; P > 0.05), vitamin use (χ2(2) = 2.9;
P > 0.05), BMI (t(52) = 0.20; P > 0.05) and previous psychiat-
ric diagnoses (χ2(5) = 4.0; P > 0.05). There were also no base-
line group differences on the BDI–II, the BIS-BAS, the
LEIDS-R and POMS subscales (all P > 0.05).
Compliance and manipulation check
Biochemical analyses of n-3 PUFAs concentrations in plasma
level showed no differences at baseline between the two groups
for EPA (t(45) = 0.92; P > 0.05), and for oleic acid
(t(45) = 1.38; P > 0.05), but a small difference was found
between the two groups in DHA concentrations (t(45) = 2.08;
P < 0.05), with the placebo group having a lower mean concen-
tration. There was a significant interaction effect of treat-
ment × time for EPA [F(1,45) = 77.04, P < 0.001] and DHA
[F(1,45) = 24.86, P < 0.001]. The n-3 PUFA group showed a
significant increase of EPA (t(21) = 8.75; P < 0.001) and of
DHA (t(21) = 7.55; P < 0.001) (η2 = 1.5). The placebo group
had equal EPA concentrations before and after treatment
(t(24) = 1.53; P > 0.05) but a small increase in DHA
(t(24) = 2.43; P < 0.05) (η2 = 0.35) (See Table 2). Self reported
compliance was excellent and there was no difference between
the two groups (χ2(4) = 1.78; p > 0.05). However, examination
of individual changes of fatty acids concentrations revealed five
outliers. Three participants in the n-3 PUFA group had a very
low increase of EPA concentrations (ΔEPA < 0.6, z < −1.4),
whereas two participants in the placebo group showed a higher
than expected increase in EPA (ΔEPA > 0.45, z > 1.8). Like the
two early drop-outs, we excluded these participants from anal-
yses since the aim of this study was to investigate the effects of
raised EPA concentrations on cognition in healthy volunteers.
In other words, we did not do an intention-to-treat analysis
since the study was not designed as a therapeutic trial but as
a challenge study.
The blinding procedure was quite successful. Nine out of 27
participants who were randomized to the n-3 PUFA group and
ten participants in the placebo group correctly guessed their
group allocation. Nine participants in the n-3 PUFA group
and four participants in the placebo group guessed wrongly,
and 21 participants had no idea about treatment assignment.
There were no differences between the groups in terms of
expectancy (χ2(2) = 3.15; p > 0.05).
Mood states
Separate rmANOVAs on each subscale showed no significant
time × treatment interactions for all subscales, except for the
fatigue subscale [F(2,94) = 3.19; P = 0.046] Between-group
comparisons at separate time points showed a trend at t0
(P = 0.07), a non-significant difference at t1 and a significant
difference after 4 weeks of supplementation, (P = 0.03). Mean
scores are presented in Table 3.
Cognition
Cognitive reactivity The time × treatment interaction was
significant for the Control/Perfectionism subscale of the
LEIDS-R [F(1,47) = 4.95; P = 0.03]. The change over time
was significant for the n-3 PUFA group (t(23) = 2.66;
Table 1 Baseline sample characteristics (means ± SD)
Treatment condition
Omega-3 Placebo
N = 27 N = 27
Females n = 21 n = 23
Age in years 22.2 ± 3.6 22.6 ± 4.1
BMI (kg/m2) 21.9 ± 2.3 21.8 ± 2.2
Previous psychiatric diagnoses
No diagnosis n = 22 n = 21
Depression n = 4 n = 4
Hypomania n = 1 n = 0
Panic disorder n = 0 n = 1
Agoraphobia n = 0 n = 1
Depressive symptoms (BDI-II) 4.1 ± 4.7 5.8 ± 5.2
Behavioural activation
Drive 11.5 ± 2.0 11.6 ± 1.9
Fun seeking 11.9 ± 2.2 11.3 ± 1.7
Reward responsiveness 17.2 ± 1.6 16.4 ± 2.3
Behavioural inhibition 18.6 ± 3.5 19.7 ± 2.9
LEIDS-R baseline 28.93 ± 13.38 32.00 ± 11.71
POMS baseline
Fatigue 2.85 ± 2.48 3.81 ± 3.14
Anger 2.15 ± 2.21 2.93 ± 2.16
Tension 2.44 ± 2.22 3.81 ± 3.88
Sadness 2.07 ± 2.97 2.26 ± 2.85
Vigour 8.63 ± 3.28 9.74 ± 3.38
BMI, body mass index; BDI-II, Beck Depression Inventory, 2nd edition.
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P = 0.01) but not for the placebo group (P > 0.05). Trends
were found for the time × treatment interaction for the Risk
Aversion subscale [F(1,47) = 3.05; P = 0.087] and the total
LEIDS-R score [F(1,47) = 3.68; P = 0.06] (See Table 3). The
change of EPA concentrations over time (ΔEPA) correlated
significantly with change of LEIDS-R-total (r = 0.35,
P = 0.02) and with the change of Control/Perfectionism
(r = 0.30, P = 0.04). No other significant correlations were
found between ΔEPA and LEIDS-R subscale change scores.
Emotional and neutral information processing
For both the Attentional and Affective Go/No-Go tests, analy-
ses showed no significant interaction effects of time × treatment
for the number of omissions, the number of false alarms and
for reaction times. The data of both tests are summarized in
Table 4. For Facial Emotion Recognition accuracy, all
time × intensity × treatment interactions were non-significant
and no significant effects on reaction times were found
(P > 0.05). On the 15 word list (memory) test, there were also
no significant time × treatment interactions for immediate
recall, delayed recall and consolidation (P > 0.05).
Decision making
Proportionate choice and deliberation times Participants
chose the experimental gamble significantly more often when
the probability of winning was high compared with when it
was low [F(1,47) = 143.83; P < 0.001]; when the expected
gains were large compared with when they were small
[F(1,47) = 63.09; P < 0.001] and less often when expected losses
were large compared with when they were small
[F(1,47) = 99.69; P < 0.001]. There were no significant two-
way interactions between probability or size of gains or size
of losses and treatment (P > 0.05). There were also no signifi-
cant three- or four-way interactions between treatment group,
probability and size of gains or losses (F < 1; P > 0.05). Delib-
eration times were not affected by the probability of winning,
Table 2 Plasma fatty acids concentrations as percentage of total fatty acids (mean ± SD)
Omega-3 Placebo
Pre Post Pre Post Interaction effect
EPA 0.51 ± 0.21 2.84 ± 1.26 0.45 ± 0.21 0.52 ± 0.24 P < 0.001
DHA 1.93 ± 0.45 2.60 ± 0.58 1.69 ± 0.36 1.81 ± 0.34 P < 0.001
Oleic Acid 17.85 ± 1.93 16.79 ± 1.62 18.76 ± 2.50 20.04 ± 2.36 P = 0.001
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
Table 3 Mood states and cognitive reactivity before and after supplementation
Omega-3 (n = 24) Placebo (n = 25) Interaction effect
Pre Post Pre Post
POMS
Fatigue 2.5 ± 2.3 2.0 ± 2.3 3.6 ± 2.8 3.6 ± 3.3 F(2,94) = 3.19; P = 0.046
Anger 1.8 ± 1.6 1.8 ± 2.1 2.8 ± 2.1 2.4 ± 2.5 F(2,94) = 0.24; P = 0.79
Tension 2.3 ± 2.1 2.0 ± 1.6 3.5 ± 3.7 2.8 ± 2.5 F(2,94) = 0.43; P = 0.65
Sadness 1.8 ± 2.7 1.6 ± 2.8 1.9 ± 2.3 1.8 ± 2.6 F(2,94) = 0.09; P = 0.91
Vigour 8.3 ± 3.1 9.7 ± 4.3 9.5 ± 3.3 10.0 ± 4.3 F(2,94) = 0.25; P = 0.78
LEIDS – R
RAV 7.6 ± 3.9 6.5 ± 3.7 7.9 ± 3.4 9.0 ± 4.0 F(1,47) = 3.05; P = 0.09
HOP 2.5 ± 2.7 2.2 ± 1.4 2.5 ± 1.8 3.3 ± 2.4 F(1,47) = 2.22; P = 0.14
CTR 5.5 ± 3.5 4.5 ± 3.0 6.7 ± 3.3 7.2 ± 4.0 F(1,47) = 4.95; P = 0.03
ACC 1.0 ± 1.2 1.1 ± 1.4 1.5 ± 2.1 1.7 ± 2.1 F(1,47) = 0.03; P = 0.85
AGG 4.7 ± 4.1 4.2 ± 4.0 4.5 ± 3.6 4.4 ± 3.7 F(1,47) = 0.34; P = 0.56
RUM 7.0 ± 3.7 6.8 ± 3.7 9.3 ± 3.7 9.6 ± 4.0 F(1,47) = 0.27; P = 0.60
Total 28.3 ± 13.6 25.3 ± 12.3 32.4 ± 12.1 35.1 ± 14.1 F(1,47) = 3.68, P = 0.06
Means ± standard deviations.
POMS, Profile of Mood States; LEIDS – R, Leiden Index of Depression Sensitivity – Revised; HOP, Hopelessness/Suicidality; ACC, Acceptance/Coping;
AGG, Aggression; CTR, Control/Perfectionism; RAV, Risk Aversion; RUM, Rumination.
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size of expected gains or size of expected losses (P > 0.05).
There were no significant interactions involving treatment
group and any of these conditions [F < 1; P > 0.05] In each
condition, the n-3 PUFA group was faster than the placebo
group in placing their gambles; however, this difference was
not statistically significant [F(1,47) = 0.19; P > 0.05]. Data are
presented in Table 5.
“Gains only” and “Losses only” trials: risk-seeking behaviour
and deliberation times As expected, participants took signif-
icantly fewer risks in gains-only trials than in losses-only trials
[F(1,47) = 128.92; P < 0.001]. On approximately 80% of trials,
participants preferred the certain gain of 30 cents over playing
a gamble with a 0.5 probability of winning 60 cents or nothing.
This effect was significantly modulated by treatment with n-3
PUFAs [F(1,47) = 6.51; P = 0.01]. In the ‘gains only’ trials, the
n-3 group showed more risk-seeking decision-making behav-
iour than the placebo group, t(47) = 2.32, P = 0.03 (see
Figure 2). In losses-only trials, participants almost always
rejected the guaranteed loss of 30 cents and preferred to play
a gamble with a 0.5 chance of losing nothing or losing 60 cents;
there were no differences between treatment groups (P > 0.05).
Participants made significantly faster choices on the ‘gains-
only’ trials in comparison with the ‘losses-only’ trials
[F(1,47) = 46.35; P < 0.001]. The n-3 PUFA group was approx-
imately 500 ms slower than the placebo group in the gains-only
trials and about 200 ms slower in the losses-only trials; how-
ever, this difference between the two groups was non-
significant [F (1,47) = 0.51; P > 0.05], and neither was the treat-
ment × trial type interaction [F(1,47) = 0.19; P > 0.05].
Table 5 Proportionate choices and mean deliberation times (±SEM) as a function of probability of winning, levels of expected gains and expected
losses and treatment group, in the decision-making task
Probability of winning Expected gains Expected losses
High Low Large Small Large Small
Proportionate choice
Omega 3 0.72 ± 0.04 0.24 ± 0.05 0.57 ± 0.04 0.39 ± 0.03 0.35 ± 0.04 0.60 ± 0.04
Placebo 0.74 ± 0.04 0.21 ± 0.05 0.56 ± 0.04 0.39 ± 0.03 0.36 ± 0.04 0.59 ± 0.03
Reaction times
Omega 3 2461 ± 259 2469 ± 214 2393 ± 232 2538 ± 223 2474 ± 216 2457 ± 240
Placebo 2665 ± 254 2546 ± 209 2582 ± 227 2628 ± 219 2555 ± 212 2655 ± 235
Table 4 Means (±SD) of misses, false alarms and mean reaction time on the attentional and affective go/no-go tasks
Omega-3 Placebo
Pre Post Pre Post
Attentional Go/no-go
Misses 1.4 ± 3.3 0.7 ± 1.3 2.9 ± 4.6 1.4 ± 2.5
False alarms 2.7 ± 3.5 1.4 ± 1.6 3.1 ± 4.1 1.7 ± 2.5
Reaction time 401.4 ± 37.3 408.5 ± 43.6 417.4 ± 50.9 408.1 ± 42.9
Affective Go/no-go
Negative valence
Misses 2.3 ± 3.0 2.1 ± 2.8 1.7 ± 1.6 1.3 ± 1.3
False alarms 1.9 ± 2.5 1.4 ± 2.0 1.2 ± 1.3 1.3 ± 1.7
RT’s 580.1 ± 63.6 581.9 ± 54.3 609.1 ± 84.2 582.1 ± 70.4
Positive valence
Misses 2.7 ± 3.4 2.4 ± 4.1 1.8 ± 1.9 1.4 ± 2.3
False alarms 1.2 ± 1.1 1.2 ± 1.1 1.6 ± 1.4 1.5 ± 1.8
RT’s 590.3 ± 57.3 590.5 ± 64.3 602.9 ± 81.1 586.2 ± 58.3
Shift blocks
Misses 1.8 ± 2.9 1.3 ± 2.1 1.0 ± 1.0 1.3 ± 2.1
False alarms 1.4 ± 1.3 1.0 ± 1.5 1.5 ± 1.1 1.5 ± 1.9
RT’s 576.7 ± 55.2 579.6 ± 51.8 591.8 ± 73.6 589.2 ± 67.3
Non-shift blocks
Misses 2.4 ± 2.4 2.8 ± 4.1 2.0 ± 1.9 1.4 ± 1.5
False alarms 1.4 ± 1.6 1.4 ± 1.7 1.2 ± 1.4 1.2 ± 1.5
RT’s 586.8 ± 65.2 592.3 ± 64.7 608.7 ± 88.6 585.9 ± 64.4
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Discussion
This study showed no effects of n-3 PUFA supplementation in
healthy volunteers on attention, memory, response inhibition
and emotion recognition. However, selective effects were
observed on cognitive reactivity and risky decision-making.
As expected, there were no effects on self-reported mood,
except for a small effect on fatigue that should be interpreted
with caution because at baseline the groups differed at the
trend level of significance. The results on the POMS are in con-
trast with Fontani, et al. (2005), who found an increase in vig-
our and a decrease in all other mood states (anger, anxiety,
depression, fatigue). The difference between studies might be
due to the fact that supplements in Fontani, et al. contained
more DHA (0.8 g/day versus 0.25 g/day in the present study).
However, EPA seems to have stronger effects on mood than
DHA (Lin and Su, 2007), and these dosages were comparable.
As the participants in the Fontani, et al. study were regular
exercisers, an interaction between n-3 PUFA supplementation
and physical exercise may also have occurred. As noted in the
introduction, we cannot be sure whether the effects in Fontani,
et al. (2005) were actually larger than placebo.
No significant differences were found between the two
groups in the number of omissions, false alarms and in reaction
times in the attentional go/no-go task involving neutral mate-
rial. This is also in contrast to Fontani, et al. (2005) who found
an effect on reaction times. A major difference between the two
studies is that, on closer look, the tasks presented as Go/No-Go
tasks by Fontani, et al. involved significant elements of vigi-
lance and short-term memory, but do not seem to measure
response inhibition. No effect of n-3 PUFA supplementation
was found on any of the outcome measures in the Affective
Go/No-Go task. In healthy samples, tryptophan depletion,
which reduces serotonergic function, resulted in slower
responses to happy but not to sad words (Murphy, et al.,
2002). Tyrosine depletion, which reduces dopaminergic func-
tion, was also associated with a sad latency bias (McLean,
et al., 2004). Apparently, any effects of n-3 PUFA supplemen-
tation on serotonergic or dopaminergic neurotransmission are
too small to affect attention and response inhibition (in relation
to both neutral or valenced stimuli) in healthy individuals. Of
course, there may also have been too little room for improve-
ment (ceiling effect). The same applies to the measures of facial
emotion recognition and memory, which were also not affected
by n-3 PUFA supplementation. These measures were included
because they had been shown to be sensitive to various short-
term manipulations of neurotransmitters (Harmer, et al., 2003;
Attenburrow, et al., 2003; Riedel, et al., 1999; Schmitt, et al.,
2000).
An effect of n-3 PUFAs on cognitive reactivity was
observed only on the Control/Perfectionism subscale of the
LEIDS-R, where the n-3 PUFA group showed decreased reac-
tivity. This scale measures the extent to which a mild dysphoric
mood triggers perfectionistic thoughts. This effect, along with a
trend-level effect on the total score, correlated with the change
of EPA and seems worthy of follow-up in future research.
The two groups showed similar patterns of decision-making
in their choices of the experimental gamble over the control
gamble across almost all conditions. Deliberation times were
also similar. Previously, Rogers, et al. (2003) found that parti-
cipants who underwent tryptophan depletion – which reduces
central serotonin activity – showed reduced discrimination
between the magnitudes of expected gains compared with
non-depleted participants. It does not necessarily follow that
opposite interventions would improve the discrimination
between the magnitude of expected gains. However, it is also
possible that the effects of n-3 PUFAs on serotonin function, if
any, are too small to alter such aspects of decision-making.
However, n-3 PUFA–treated participants showed less risk-
aversion in the face of certain gains. Previous studies with the
risky decision-making task have not found effects on such non-
normative aspects of decision-making. Thus, the reflection
effect was consistently found, with no differences between
treatment groups, following tryptophan depletion (Rogers,
et al., 2003), the β-blocker propranolol (Rogers, et al., 2004),
tyrosine depletion (Scarna, et al., 2005) and tetrahydrocannabi-
nol (Rogers, et al., 2007). It should be noted that each of these
studies used a version of the task in which the differences
between the largest and the smallest gains, losses and probabil-
ities were all greater than those of the version used in the pres-
ent study. The present version required participants to make
finer discriminations between different levels of reinforcement
when making choices, possibly improving the task’s sensitivity.
Consistent with this possibility, we have found similar changes
in the reflection effect following 2 weeks of treatment with
tryptophan as a dietary supplement, and following single
doses of duloxetine (Rogers, et al., unpublished article).
Figure 2 Proportion of choices of the guaranteed outcome in the ‘gains-
only’ and ‘losses-only’ trials by the omega-3 group and placebo, in the
decision-making task.
838 Omega-3 and depression-related cognition
In the present experiment, the effects of n-3 PUFAs were
expressed as increased risk-seeking behaviour compared with
treatment with placebo. Because this finding was accompanied
by longer deliberation times, we suggest that this difference
does not reflect impulsiveness but rather a willingness to take
calculated risks. The lack of effects on the two Go/No-Go tasks
also argues against an explanation in terms of elevated impul-
sivity. Previous research on risk-taking tendencies and mood
suggests that under a low-risk situation a positive mood may
induce more risky decision-making in a gambling task, as the
likely gain may enhance or at least maintain the positive mood
(Isen and Geva, 1987). In the gains-only trials of the gambling
task, choosing the guarantee-gain gamble presumably requires
less mental effort expenditure than when choosing the risky
gamble. Meijman, et al. (1992; as cited in Hockey, et al.,
2000) found that people under fatigue put less mental effort
on cognitive probe tasks and may prefer activities requiring
less effort and avoid engaging in high-level control actions.
This may be related to lower reported fatigue of the n-3
PUFA group on the POMS. These results seem to indicate
that participants were more willing to put more mental effort
in their decision-making choices and eventually were more will-
ing to engage in risky behaviour.
To our knowledge this was the first study to examine the
effects of n-3 PUFA supplements on depression-related cogni-
tive functioning in healthy individuals. By investigating a
healthy sample, we could circumvent some potential confoun-
ders such as illness chronicity and concomitant medications.
Although we found few effects of n-3 PUFAs on cognition,
the relatively short duration of the intervention, the initial
high levels of DHA in the n-3 PUFA group and the change
in DHA levels in the placebo group may all have masked
other effects of the manipulation. The sample size was large
enough to detect moderately large effects with the conventional
level of statistical power (0.8); hence, subtler effects may have
gone undetected. However, the positive findings should also be
considered with caution because we made a large number of
comparisons between groups. Finally, it should be noted that
the decision-making task was only administered at post-test,
which means that the difference in the gains-only trials cannot
be confidently attributed to treatment. A logical next step in
research would be to examine cognitive effects of n-3 PUFAs
in depression-vulnerable samples, characterized by history of
depression, family history of depression or genotype.
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